Study Summary
The purpose of this phase I study is to test the safety of different dose levels of specially prepared cells collected called "modified T cells". In the screening part of this study the tumor was found to have a protein called MUC16. This protein is present on about 70% of ovarian cancers. The investigators want to find a safe dose of modified T cells for patients with this type of cancer that has progressed after standard chemotherapy. We also want to find out what effects these modified T cells have on the patient and their cancer.
Want to learn more about this trial?
Request More InfoInterventions
Production of Genetically-modified T cellsPROCEDURE
No description available.
CyclophosphamideDRUG
No description available.
IP Catheter InsertionDEVICE
No description available.
Infusion of 4H11-28z/fIL-12/EGFRt+ Genetically-modified T cellsGENETIC
Patients who do not have sufficient CAR T cells for the assigned dose cohort will be treated in the cohort for which cells are available.
FludarabineDRUG
fludarabine dose 25-30 mg/m2 x 3 days
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | New York | New York | United States |